GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » EQL Pharma AB (FRA:7JK) » Definitions » Gross Margin %

EQL Pharma AB (FRA:7JK) Gross Margin % : 40.25% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is EQL Pharma AB Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. EQL Pharma AB's Gross Profit for the three months ended in Mar. 2024 was €2.78 Mil. EQL Pharma AB's Revenue for the three months ended in Mar. 2024 was €6.90 Mil. Therefore, EQL Pharma AB's Gross Margin % for the quarter that ended in Mar. 2024 was 40.25%.

Warning Sign:

EQL Pharma AB gross margin has been in long-term decline. The average rate of decline per year is -5.1%.


The historical rank and industry rank for EQL Pharma AB's Gross Margin % or its related term are showing as below:

FRA:7JK' s Gross Margin % Range Over the Past 10 Years
Min: 23.36   Med: 47.85   Max: 69.93
Current: 43.55


During the past 12 years, the highest Gross Margin % of EQL Pharma AB was 69.93%. The lowest was 23.36%. And the median was 47.85%.

FRA:7JK's Gross Margin % is ranked worse than
57.2% of 986 companies
in the Drug Manufacturers industry
Industry Median: 46.51 vs FRA:7JK: 43.55

EQL Pharma AB had a gross margin of 40.25% for the quarter that ended in Mar. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for EQL Pharma AB was -5.10% per year.


EQL Pharma AB Gross Margin % Historical Data

The historical data trend for EQL Pharma AB's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EQL Pharma AB Gross Margin % Chart

EQL Pharma AB Annual Data
Trend Dec14 Dec15 Dec16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 51.12 28.47 23.36 44.57 43.55

EQL Pharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.57 46.61 40.11 47.71 40.25

Competitive Comparison of EQL Pharma AB's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EQL Pharma AB's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's Gross Margin % distribution charts can be found below:

* The bar in red indicates where EQL Pharma AB's Gross Margin % falls into.



EQL Pharma AB Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

EQL Pharma AB's Gross Margin for the fiscal year that ended in Mar. 2024 is calculated as

Gross Margin % (A: Mar. 2024 )=Gross Profit (A: Mar. 2024 ) / Revenue (A: Mar. 2024 )
=10.2 / 23.343
=(Revenue - Cost of Goods Sold) / Revenue
=(23.343 - 13.177) / 23.343
=43.55 %

EQL Pharma AB's Gross Margin for the quarter that ended in Mar. 2024 is calculated as


Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=2.8 / 6.904
=(Revenue - Cost of Goods Sold) / Revenue
=(6.904 - 4.125) / 6.904
=40.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


EQL Pharma AB  (FRA:7JK) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

EQL Pharma AB had a gross margin of 40.25% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


EQL Pharma AB Gross Margin % Related Terms

Thank you for viewing the detailed overview of EQL Pharma AB's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


EQL Pharma AB (FRA:7JK) Business Description

Traded in Other Exchanges
Address
Stortorget 1, 3rd Floor, Lund, SWE, 222 23
EQL Pharma AB is a pharmaceutical company engaged in developing and selling medicines to pharmacies and hospitals. The products offered by the company include generics and parallel imports. It operates and markets products to Nordic countries of Sweden, Denmark, Finland and Norway.

EQL Pharma AB (FRA:7JK) Headlines

No Headlines